Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

被引：0
|
作者：
Ravi Potluri
Sandip Ranjan
Hitesh Bhandari
Helen Johnson
Andriy Moshyk
Srividya Kotapati
机构：
[1] SmartAnalyst Inc.,
[2] SmartAnalyst India Pvt. Ltd.,undefined
[3] Bristol-Myers Squibb,undefined
[4] Bristol-Myers Squibb,undefined
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Advanced melanoma; Melanoma; Nivolumab; Ipilimumab; Healthcare cost comparison; CheckMate 067; NCT01844505;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [2] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Potluri, Ravi
    Ranjan, Sandip
    Bhandari, Hitesh
    Johnson, Helen
    Moshyk, Andriy
    Kotapati, Srividya
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
  • [3] COMPARISON OF HEALTHCARE COSTS IN FRANCE OF COMBINATION NIVOLUMAB AND IPILIMUMAB TREATMENT VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Bregman, B.
    Moshyk, A.
    Johnson, H. M.
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [4] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
    Ribas, Antoni
    Martin-Algarra, Salvador
    Bhatia, Shailender
    Hwu, Wen-Jen
    Slingluff, Craig L.
    Sharfman, William H.
    Hodi, F. Stephen
    Urba, Walter J.
    Luke, Jason J.
    Haanen, John B.
    Callahan, Margaret K.
    Wolchok, Jedd D.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Young, Tina C.
    Qureshi, Anila
    Horak, Christine E.
    CANCER RESEARCH, 2017, 77
  • [5] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Dummer, R.
    Smylie, M.
    Rutkowski, P.
    Ferrucci, P. F.
    Hill, A.
    Wagstaff, J.
    Carlino, M. S.
    Haanen, J. B.
    Maio, M.
    Marquez-Rodas, I.
    McArthur, G. A.
    Ascierto, P. A.
    Long, G. V.
    Callahan, M. K.
    Postow, M. A.
    Grossmann, K.
    Sznol, M.
    Dreno, B.
    Bastholt, L.
    Yang, A.
    Rollin, L. M.
    Horak, C.
    Hodi, F. S.
    Wolchok, J. D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (01): : 23 - 34
  • [6] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
    Valsecchi, Matias E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13): : 1270 - 1270
  • [7] HEALTH CARE COST COMPARISON ANALYSIS OF NIVOLUMAB plus IPILIMUMAB REGIMEN, NIVOLUMAB MONOTHERAPY, AND IPILIMUMAB MONOTHERAPY UTILIZING CLINICAL TRIAL DATA: A EUROPEAN PERSPECTIVE
    Potluri, R.
    Sabater, J.
    Bhandari, H.
    Ranjan, S.
    Kotapati, S.
    VALUE IN HEALTH, 2016, 19 (03) : A144 - A144
  • [8] Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Rollin, Linda M.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Hodi, F. Stephen
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21): : 2006 - 2017
  • [9] Retrospective Analysis of Neutrophil-to-Lymphocyte Ratio in Patients with Melanoma Who Received Ipilimumab Monotherapy or Ipilimumab in Combination with Nivolumab in Japan
    Matsumura, Yuka
    Kawarada, Yuki
    Matsuo, Momo
    Yokota, Kenji
    Mizoguchi, Hiroyuki
    Akiyama, Masashi
    Yamada, Kiyofumi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2023, 46 (03) : 427 - 431
  • [10] Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia
    Takuya Maeda
    Azusa Hiura
    Jiro Uehara
    Rino Toyoshima
    Tomoe Nakagawa
    Koji Yoshino
    European Journal of Dermatology, 2021, 31 : 662 - 664
12345